Loading stock data…
Co-Diagnostics (CODX)
$2.98-0.08 (-2.61%)
After Hours$3.06+0.08 (+2.68%)· Last close Jun 29
Co-Diagnostics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Co-Diagnostics, Inc. in the Healthcare sector is trading at $2.98 with a market capitalization of $13M. The stock is currently near its 52-week low of $1.26, remaining 51.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $145,954↓ | $263,922↑ | $145,380↓ | $162,910↑ | $50,277 |
| Gross Profit | -$47,814↓ | $121,526↑ | $119,095↓ | $130,804↑ | $28,687 |
| Operating Income | -$9.21M↓ | -$7.66M↓ | -$7.01M↑ | -$8.06M↑ | -$8.55M |
| Net Income | -$9.14M↑ | -$25.75M↓ | -$5.89M↑ | -$7.73M↓ | -$7.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-302.34%
Volume
Today's trading volume
170,700
Recent News
Is Co-Diagnostics National Security’s Next Diagnostic Pick?
Global health emergencies are shifting sovereign biodefense strategies toward decentralized diagnostic networks capable of deploying rapid stockpiles.
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
On the line today from Co-Diagnostics, we have Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer. Earlier today, Co-Diagnostics released financial results from the fourth quarter and full year ended December 31, 2025.
Top Midday Gainers
Braiin (BRAI) said Tuesday it collaborated with Switchcraft to enable embedded utility and telecom s
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet
Co-Diagnostics shares surged nearly 80% on Tuesday after the company expanded development efforts for a PCR test targeting the Bundibugyo strain of the Ebola virus.
Co-Diagnostics Develops Ebola Assay Strategy Following WHO Emergency Alert (CODX)
The company said it is prepared to rapidly deploy a Bundibugyo virus Ebola test if outbreak conditions require expanded diagnostic response capabilities. Key Investor TakeawaysCo-Diagnostics (NASDAQ:CODX) completed an assay development strategy targeting the Bundibugyo strain of Ebola virus currently linked to outbreaks in Africa.